Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals
Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole, Lisa I. Backus – 27 February 2017 – Reactivation of hepatitis B virus (HBV) has been reported in hepatitis C virus–infected individuals receiving direct‐acting antiviral (DAA) therapy. The overall risk among patients with current or prior HBV infection in the context of DAA treatment is unknown. The aim of this evaluation was to identify and characterize HBV reactivation among veterans treated with oral DAA therapy. This retrospective evaluation included 62,290 hepatitis C virus–infected veterans completing oral DAA treatment.